"The Effect of Comprehensive Non-pharmacological Treatment on Metabolic Disorders in Type 2 Diabetic Patients"

NCT ID: NCT04632823

Last Updated: 2020-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-01

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the effectiveness of comprehensive non-pharmacological treatment on metabolic disorders in type 2 diabetic patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients in the intervention group will participate in a comprehensive non-pharmacological treatment of type 2 diabetes, the main components are:

* changing the meal plan (individual and group counseling, assistance in developing menus and determining the calorie intake, keeping a food diary)
* individually dosed physical exercises using specific exercise program;
* comprehensive training (course of interactive lessons, self-control training). The program included group sessions with a team of specialists: nutritionist, endocrinologist, physical therapy doctor and included 3 sessions per week for 24 weeks. Each visit included teaching patients in a group format and in an interactive form (classes with specialists alternated), performing physical exercises using the specific exercise program under the supervision of a physiotherapy physician, evaluating medical indicators, and a self-control diary.

Patients in the control group will not participate in group sessions, but they had the opportunity to receive non-pharmacological care provided in the framework of free outpatient care. Their indicators will be recorded during a routine visit to the doctor at the baseline, after 12 and 24 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

type 2 diabetes mellitus non-pharmacological treatment lifestyle intervention structured program

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective, single-center
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Comprehensive non-pharmacological program intervention

The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.

Group Type EXPERIMENTAL

Comprehensive Non-pharmacological Treatment Program

Intervention Type COMBINATION_PRODUCT

dietary supplement, specific type of exercise, self-management education

Usual diabetes care

This group is control, the patients receive usual diabetes care routines.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Comprehensive Non-pharmacological Treatment Program

dietary supplement, specific type of exercise, self-management education

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* medically diagnosed with type 2 diabetes mellitus
* HbA1c result of ≤7.0% within the past 2 months
* body mass index (BMI) of ≥26 kg/m\^2
* hypoglycemic therapy: metformin only

Exclusion Criteria

* pregnancy
* the use of other hypoglycemic drugs
* the use of medication for weight loss
* cardiovascular diseases (heart attack or cardiac procedure within the past 3 months)
* had stroke or history of treatment for transient ischemic attacks in the past 3 months
* had chronic renal failure or were on dialysis
* any conditions that do not allow the patient to perform the complex of the proposed physical exercises
Minimum Eligible Age

45 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Astana Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Viktoriya Li

PhD, Head of Rehabilitation

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Viktoriya Li, PhD

Role: PRINCIPAL_INVESTIGATOR

Astana Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

West Kazakhstan Marat Ospanov Medical University

Aktobe, Aktobe Region, Kazakhstan

Site Status ACTIVE_NOT_RECRUITING

Astana Medical University

Astana, , Kazakhstan

Site Status RECRUITING

The Center for Preventive Medicine and Life Extension of Nur-Sultan

Astana, , Kazakhstan

Site Status RECRUITING

National Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation

Moscow, , Russia

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Kazakhstan Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Viktoriya Li, PhD

Role: CONTACT

Phone: +77785568055

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yerbolat Dalenov, Professor

Role: primary

Viktoriya Li, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AstanaMU-1

Identifier Type: -

Identifier Source: org_study_id